Evidence at a glance
Human clinical evidence 2 of 3 (moderate), preclinical evidence 2 of 3 (moderate).
My read of the published evidence, not a rating of whether it works. Preclinical findings cannot establish human benefit.
What is tesamorelin?
Tesamorelin is a stabilized synthetic analogue of GHRH, the hypothalamic hormone that tells your pituitary to release growth hormone. Native GHRH degrades quickly; tesamorelin carries a chemical modification at one end that slows the enzymes down, making it practical as a daily injection. It was developed by Theratechnologies, a Montreal biotech, which gives it a rare distinction on this list: a peptide with genuinely Canadian roots.
It reached the market as Egrifta, approved for one specific problem: the excess visceral abdominal fat that can accumulate in people with HIV on antiretroviral therapy, a condition called lipodystrophy. That narrow, real approval is the anchor for everything else said about it.
Why researchers are interested
Rather than injecting growth hormone directly, tesamorelin nudges the pituitary to make more of its own, preserving the body's natural pulsatile release and its feedback brakes. IGF-1 and somatostatin can still push back. In principle this makes it gentler than exogenous growth hormone, which overrides those controls entirely.
The downstream interest centres on visceral fat, the metabolically noisy fat packed around abdominal organs. Growth hormone is lipolytic, and visceral fat appears especially responsive to it. Because visceral adiposity tracks with cardiovascular and metabolic risk, a drug that selectively shrinks it is interesting far beyond the HIV population. That is exactly how tesamorelin escaped its niche and entered longevity-clinic vocabulary.
| Sermorelin | Tesamorelin | CJC-1295 | Ipamorelin | |
|---|---|---|---|---|
| What it is | GHRH fragment (1 to 29) | Stabilized GHRH analogue | Long-acting GHRH analogue that binds albumin | Ghrelin-receptor agonist |
| Acts on | GHRH receptor | GHRH receptor | GHRH receptor | Ghrelin receptor (GHS-R1a) |
| Regulatory status | Original approved product discontinued; compounded in the US; no Canadian product | Approved in the US, and previously in Canada, for HIV-associated lipodystrophy only | Never authorized; development discontinued | Never authorized; development discontinued |
| Human evidence | Pediatric GH-deficiency trials, dated | Two Phase 3 trials in HIV lipodystrophy | Early-phase pharmacology studies only | Small volunteer studies; one failed ileus trial |
Regulatory status
This is where “it depends” earns its keep. Tesamorelin is an authorized prescription medicine in the U.S. and has held Canadian authorization, but strictly for HIV-associated lipodystrophy as a specific product. Prescribing it to a generally healthy person chasing body composition is off-label at best; buying “tesamorelin” from a peptide website is something else entirely: an unauthorized product with no verified contents.
What human research shows
Two Phase 3 randomized trials in people with HIV-associated lipodystrophy showed that tesamorelin reduced visceral adipose tissue, on the order of 15–18% over six months versus placebo, with the fat returning after discontinuation. Smaller studies have explored effects on liver fat in HIV-associated fatty liver disease, with encouraging imaging results, and pilot work has examined cognition in older adults.
Note what is missing: large randomized trials in healthy people using it for body composition or longevity. The rigorous evidence lives inside a specific patient population; the popular use case lives outside it. Small studies and biomarker changes do not close that gap.
What early research shows
Preclinical and mechanistic work on tesamorelin fills in the pharmacology: receptor binding, growth hormone and IGF-1 responses, effects on adipocytes. There is also a deeper, unresolved tension in the animal literature: growth hormone signalling is one of the pathways whose *reduction* extends lifespan in mice. Cell and animal data cannot say whether raising GH pulses in a healthy middle-aged human is a net good, and the longevity field is genuinely split on the question.
What it's being studied for
Beyond its approved indication, researchers are investigating tesamorelin for:
- Liver fat and steatohepatitis, initially in people with HIV
- Visceral adiposity in other populations
- Cognitive function in older adults with mild impairment
- Body-composition changes alongside growth hormone and IGF-1 responses
- Muscle outcomes in wasting-related conditions
What remains uncertain
The healthy-user question dominates: nobody has shown that tesamorelin improves long-term health outcomes in people without lipodystrophy, and the GH-longevity paradox cuts the other way. Effects reverse on discontinuation, implying indefinite use for sustained benefit, with unknown long-term consequences, including theoretical concerns about IGF-1 elevation. Glucose tolerance requires monitoring even within the approved use.
And for grey-market buyers, the standard caveat applies with full force: unverified identity, unverified sterility, unverified dose.
What people report
In longevity and biohacking circles, tesamorelin users report leaner midsections, better sleep, and improved recovery. The first claim at least rhymes with the trial data, though those trials were in a different population. The rest is harder to read: people who start a growth-hormone peptide are rarely doing nothing else, and sleep and recovery are exquisitely sensitive to expectation.
A visible change in the mirror after months of concurrent training and dieting is not evidence the peptide did it. That distinction, between a plausible anecdote and a demonstrated effect, is the entire game with this compound.
Sources
- Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. New England Journal of Medicine, 2007.
